IVVD
Invivyd, Inc.
NASDAQ · Healthcare · Biotechnology · US
$0.61
−1.39%Price chart
Sep 18Sep 23Sep 28Oct 1Oct 6Oct 9Oct 14Oct 19
Key dataOct 19, 2026
Open$0.64
From 52W high−78.82%
Volume4.48M
Market cap$179.80M
P/E (TTM)—
P/S (TTM)3.1x
Div yield—
Key dataOct 19, 2026
Open
$0.64
From 52W high
−78.82%
Volume
4.48M
Market cap
$179.80M
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−0.3x
P/E (TTM)
—
RSI (14)
38.6
MomentumView details →
1D Return
−1.39%
YTD Return
−74.27%
SummaryUpdated Jun 1, 2026
Invivyd, Inc. (NASDAQ:IVVD) is a clinical-stage biopharmaceutical company founded in 2020 and based in Waltham, Massachusetts. Originally incorporated as Adagio Therapeutics, the company went public in August 2021 and later rebranded to Invivyd. The company specializes in developing monoclonal antibody therapies specifically designed to protect immunocompromised patients from infectious diseases, with its primary focus on COVID-19 prevention and treatment. Invivyd has successfully brought its lead product <b>PEMGARDA</b> to market and is actively developing next-generation antibody treatments while expanding its pipeline to include other respiratory viruses.
Similar companies
Latest newsMore news →
Invivyd and the SPEAR Study Group announced the initiation of the FLINTLOCK Phase 2 clinical trial evaluating VYD2311 in individuals with Long COVID or Post-Vaccination Syndrome.5d agoInvivyd, Inc. granted six newly hired non-executive employees options to purchase an aggregate of 157,500 shares of its common stock on October 1, 2026, under its 2026 Inducement Plan and Nasdaq Listing Rule 5635(c)(4).14d agoInvivyd granted options to purchase 277,500 shares of common stock to ten newly hired non-executive employees as an inducement for employment.76d ago